Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second pivotal Phase III trial to evaluate the efficacy of NB-01 in diabetic neuropathic pain

Next Previous
Search
Trial Profile

Second pivotal Phase III trial to evaluate the efficacy of NB-01 in diabetic neuropathic pain

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NB 01 (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Sponsors MThera Pharma

    • Most Recent Events

    • 18 Nov 2024 According to a NeuroBo Pharmaceuticals media release, NeuroBo Pharmaceuticals, Inc. has changed its name to MetaVia Inc.
    • 30 Jul 2024 According to NeuroBo Pharmaceuticals, the company has signed a an exclusive license agreement, providing MThera Pharma Co., Ltd. (MTHERA) with the rights to NB-01 for the treatment of painful diabetic neuropathy. The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States and South Korea, for the future commercialization of NB-01.
    • 30 Mar 2020 According to NeuroBo Pharmaceuticals, because of global health emergency caused by the COVID-19 pandemic to conserve financial resources, company has decided to postpone the initiation of Phase 3 clinical trials for NB-01.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top